Yanhong Deng

2026

• EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer From a Phase Ib/II, Open-Label, Multicenter Study.

  Xu T, Parseghian C, Zhang Y, Chen Z, Qin Y, Zhang W, Deng Y, Pan H, Gu S, Li C, Ren F, Wu Y, Lu Q, Zhang M, Wang R, Zhu Y, Shen L, Li J. EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer From a Phase Ib/II, Open-Label, Multicenter Study. Clinical Cancer Research 2026, of1-of11. PMID: 42635595, DOI: 10.1158/1078-0432.ccr-26-2128.

  Peer-Reviewed Original Research

  Altmetric

• Paclitaxel oral solution versus paclitaxel injection as second-line therapy for advanced gastric cancer: a multicenter, open-label, randomized phase III trial

  Li J, Huang M, Deng T, Bai Y, Liu T, Pan Y, Yu J, Pan H, Xu H, Wang J, Ye F, Wang J, Wu J, Cang S, Chen K, Zhang J, Zhang J, Ling Y, Zhong H, Fu G, Liu H, Huang L, Pan Y, Zhang L, Liu L, Ye X, Wu M, Zheng Z, Huang J, Liang X, Liu Y, Ding Y, Bai C, Yang L, Yan P, Miao J, Lu H, Bi Q, Zhou Y, Peng Y, Lin H, Deng Y, Zhong D, Gao C, Liu H, Tan S, Yi T, Liu Y, Song L, Chen Y, Qin S. Paclitaxel oral solution versus paclitaxel injection as second-line therapy for advanced gastric cancer: a multicenter, open-label, randomized phase III trial. ESMO Open 2026, 11: 108312. PMID: 42617423, PMCID: PMC13520883, DOI: 10.1016/j.esmoop.2026.108312.

  Peer-Reviewed Original Research

  Altmetric

• RMI2 depletion recovers cGAS-STING signaling to enhance immunotherapy in colorectal cancer

  Cai R, Huang E, Liu Y, Lyu X, Fu Y, Bai F, Guo C, Qin G, Xie Y, Zhang J, Deng Y, Zhan W. RMI2 depletion recovers cGAS-STING signaling to enhance immunotherapy in colorectal cancer. Cell Death & Disease 2026 DOI: 10.1038/s41419-026-09148-4.

  Peer-Reviewed Original Research

  Altmetric

• Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial

  Hu H, Shen X, Li Y, Zhou J, Liu P, Zhang J, Hou Y, Wang X, Deng J, Zheng Z, Li J, Lan P, Wu X, Kang L, Huang M, He Z, He X, Yang Z, Huang L, Wang H, Wang H, Luo S, Chen D, Xie X, Zhang Y, Zhai X, Li S, Li W, Hu J, Yang T, Wang C, Deng W, Huang Y, Cao W, Li F, Shi L, Ling L, Deng Y. Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial. The Lancet Oncology 2026, 27: 1020-1030. PMID: 42385761, DOI: 10.1016/s1470-2045(26)00220-2.

  Peer-Reviewed Original Research

  Altmetric

• VG161 oncolytic virus remodels the tumor microenvironment by expanding CD3+ macrophages and enhancing antitumor immunity

  Bai F, Qin G, Li J, Zhan W, Fu Y, Wu Z, Cheng Y, Deng Y. VG161 oncolytic virus remodels the tumor microenvironment by expanding CD3+ macrophages and enhancing antitumor immunity. Cancer Letters 2026, 657: 218696. PMID: 42362102, DOI: 10.1016/j.canlet.2026.218696.

  Peer-Reviewed Original Research

  MeSH Keywords

• Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial

  Yuan J, Gong J, Peng Z, Xu H, Yang J, Wei J, Jiang H, Deng Y, Wang Y, Qi C, Lyu C, Sun Q, Mu L, Song L, Zhang X, Shen L. Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial. British Journal Of Cancer 2026, 135: 924-930. PMID: 42337043, PMCID: PMC13534696, DOI: 10.1038/s41416-026-03511-0.

  Peer-Reviewed Original Research

  Altmetric

  MeSH Keywords

• PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer

  Cai R, Zhan W, Lyu X, Yang X, Wu Z, Cheng Y, Guo C, Feng J, Fu Y, Xie Y, Qin G, Deng Y, Zhang J. PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer. Gut 2026, gutjnl-2026-338195. PMID: 42173678, DOI: 10.1136/gutjnl-2026-338195.

  Peer-Reviewed Original Research

  Citations

• Neoadjuvant mFOLFOXIRI with or without cadonilimab versus mFOLFOX6 in locally advanced colorectal cancer: A randomized phase 2 trial (OPTICAL-2)

  Zhang J, Qi S, Hu H, He X, Huang L, Zhou J, Wang H, Wu X, Kang L, Huang M, He Z, Wang H, Chen D, Zhai X, Xie X, Ling J, Zhang Y, Hu J, Li S, Wu Z, Yang T, Cai R, Cai Y, Zhong L, Li W, Shi L, Wang C, Huang Y, Zhao Y, Cao W, Qin G, Deng Y. Neoadjuvant mFOLFOXIRI with or without cadonilimab versus mFOLFOX6 in locally advanced colorectal cancer: A randomized phase 2 trial (OPTICAL-2). Med 2026, 7: 101141. PMID: 42134324, DOI: 10.1016/j.medj.2026.101141.

  Peer-Reviewed Original Research

  Citations

  Altmetric

  MeSH Keywords

• Mortality and Infectious Adverse Events in Neutropenic Patients Undergoing Gastrointestinal Endoscopic Procedures: A Systematic Review and Meta-Analysis

  Bahirwani J, Chugh R, Tran A, Ogurick A, Grimshaw A, Ciarleglio M, Deng Y, Al-Bawardy B, Hung K, Laine L. Mortality and Infectious Adverse Events in Neutropenic Patients Undergoing Gastrointestinal Endoscopic Procedures: A Systematic Review and Meta-Analysis. Gastro Hep Advances 2026, 5: 100994. PMID: 42293779, PMCID: PMC13264052, DOI: 10.1016/j.gastha.2026.100994.

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

• Cetuximab plus capecitabine every three weeks as first-line maintenance therapy for RAS/BRAF wild-type metastatic colorectal cancer: a phase Ib dose-escalation study

  Xie X, Lin Z, Li W, Xie Y, Zhang J, Hu H, Li S, Zhai X, Shi L, Deng Y. Cetuximab plus capecitabine every three weeks as first-line maintenance therapy for RAS/BRAF wild-type metastatic colorectal cancer: a phase Ib dose-escalation study. Npj Precision Oncology 2026, 10: 250. PMID: 42032138, PMCID: PMC13320180, DOI: 10.1038/s41698-026-01429-7.

  Peer-Reviewed Original Research